TACSTD2 and endometrial cancer: Our previous research work and current results demonstrate that TROP2 is overexpressed in a large percentage of endometrial cancer cases and that primary endometrial cancer cell lines overexpressing TROP2 are highly susceptible to killing in vitro by Dato-DXd.